4.7 Article

Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion

Journal

BLOOD
Volume 118, Issue 17, Pages 4591-4594

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-337501

Keywords

-

Categories

Funding

  1. Anatomic Pathology Section, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

Ask authors/readers for more resources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive malignancy derived from precursors of plasmacytoid dendritic cells. We analyzed 21 cases with array-based comparative genomic hybridization (aCGH). Complete or partial chromosomal losses largely outnumbered the gains, with common deleted regions involving 9p21.3 (CDKN2A/CDKN2B), 13q13.1-q14.3 (RB1), 12p13.2-p13.1 (CDKN1B), 13q11-q12 (LATS2), and 7p12.2 (IKZF1) regions. CDKN2A/CDKN2B deletion was confirmed by FISH. This scenario argues for disruption of cell cycle at G1/S transition, representing a genetic landmark of BPDCN, and possibly contributing to its pathogenesis. Statistical analysis of overall survival in our series highlighted an association of poor outcome with biallelic loss of locus 9p21.3. We suggest that, in the absence of reliable parameters for predicting prognosis in BPDCN other than age, tumor stage, and/or clinical presentation, simple methods, such as FISH for CDKN2A/CDKN2B, could help to identify the most aggressive cases. (Blood. 2011; 118(17): 4591-4594)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Oncology

Molecular remission is an independent predictor of progression-free survival in patients with Waldenstrom macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study

Marzia Varettoni, Silvia Zibellini, Michele Merli, Daniela Drandi, Cristina Jimenez, Daniela Furlan, Virginia Valeria Ferretti, Nicole Fabbri, Irene Dogliotti, Chiara Varraso, Martina Ferrante, Emilia Cappello, Veronica Peri, Chiara Cavalloni, Michela Borriero, Giulia Vittoria Facchetti, Simone Ferrero, Luca Arcaini, Ramon Garcia-Sanz

HEMATOLOGICAL ONCOLOGY (2023)

Article Oncology

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Michele Merli, Isacco Ferrarini, Francesco Merli, Alessandro Busca, Roberto Mina, Brunangelo Falini, Riccardo Bruna, Roberto Cairoli, Monia Marchetti, Alessandra Romano, Michele Cavo, Luca Arcaini, Livio Trentin, Chiara Cattaneo, Enrico Derenzini, Nicola Stefano Fracchiolla, Francesco Marchesi, Annamaria Scattolin, Atto Billio, Monica Bocchia, Massimo Massaia, Carlo Gambacorti-Passerini, Francesca Romana Mauro, Massimo Gentile, Sara Mohamed, Matteo Giovanni Della Porta, Elisa Coviello, Daniela Cilloni, Giuseppe Visani, Augusto Bramante Federici, Maria Chiara Tisi, Laura Cudillo, Sara Galimberti, Filippo Gherlinzoni, Livio Pagano, Anna Guidetti, Lorenza Bertu, Paolo Corradini, Francesco Passamonti, Carlo Visco

Summary: A study analyzed data from CLL patients with COVID-19 in Italy and found that male sex, age over 70, recent CLL treatment, and COVID-19 severity were independently associated with poor survival. The study revealed a dismal COVID-related outcome in a significant fraction of CLL patients.

HEMATOLOGICAL ONCOLOGY (2023)

Article Hematology

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Christian Pecquet, Nicolas Papadopoulos, Thomas Balligand, Ilyas Chachoua, Amandine Tisserand, Audrey Nedelec, Didier Vertommen, Anita Roy, Caroline Marty, Harini Nivarthi, Mira El-Khoury, Eva Hug, Andrea Majoros, Erica Xu, Oleh Zagrijtschuk, Tudor E. Fertig, Daciana S. Marta, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Casetti, Elisa Rumi, Daniela Pietra, Chiara Cavalloni, Luca Arcaini, Mario Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Yoko Edahiro, Marito Araki, Roman Lesyk, Veronika Buxhofer-Ausch, Sonja Heibl, Florence Pasquier, Violaine Havelange, Isabell Plo, William Vainchenker, Robert Kralovics, Stefan N. Constantinescu

Summary: Mutant CALR proteins bind to and activate the TpoR in cells, driving the development of myeloproliferative neoplasms. These mutant CALR proteins can be found in patient plasma complexed with sTFR1, which increases their stability. They can specifically interact with TpoR on target cells and promote thrombopoietin-independent colony formation.

BLOOD (2023)

Article Oncology

Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature

Chiara Rossi, Sara Fraticelli, Marianna Fanizza, Alberta Ferrari, Elisa Ferraris, Alessia Messina, Angelica Della Valle, Chiara Annunziata Pasqualina Anghelone, Angioletta Lasagna, Gianpiero Rizzo, Lorenzo Perrone, Maria Grazia Sommaruga, Giulia Meloni, Silvia Dallavalle, Elisabetta Bonzano, Marco Paulli, Giuseppe Di Giulio, Adele Sgarella, Marco Lucioni

Summary: Accurate evaluation of breast cancer on bioptic samples is crucial for guiding therapeutic decisions. This study assessed the concordance of hormone receptors and Ki-67 between biopsy and surgical specimens. The results suggest suboptimal concordance for ER-low-positive, c-erbB2/HER2, and Ki-67, indicating the need for further training in this area.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Article Biochemistry & Molecular Biology

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Sara Fraticelli, Marco Lucioni, Giuseppe Neri, Deborah Marchiori, Caterina Cristinelli, Michele Merli, Rodolfo Monaco, Tiziana Borra, Antonio Lazzaro, Silvia Uccella, Luca Arcaini, Marco Paulli

Summary: Castleman disease (CD) is a rare lymphoproliferative disorder with various clinico-pathological subtypes. The pathogenesis of CD is still uncertain, but alterations in T-cell subsets may contribute to the development of CD. In this study, the distribution of T-cell subsets in the clinico-pathological spectrum of CD was investigated. The results showed decreased CD4/CD8 ratio and lower number of FOXP3+ T-reg cells in CD cases compared to non-specific reactive lymph nodes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Dermatology

Indeterminate cell histiocytosis: A systematic review of the literature with a comprehensive revision of clinical, histopathological, and molecular features

Simone Zanella, Emilio Berti, Arturo Bonometti

Summary: Indeterminate cell histiocytosis (ICH) is a rare disorder primarily affecting the skin, especially in adults, and needs to be differentiated from other diseases through clinical and histological examination. This systematic review analyzed the literature and identified associations between ICH and the development of hematological neoplasms in adults. The review also discusses the genetics, cell of origin, and treatment options for different clinical subgroups of ICH.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Oncology

The molecular landscape of breast mucoepidermoid carcinoma

Konstantinos Venetis, Elham Sajjadi, Mariia Ivanova, Silvia Andaloro, Simona Pessina, Chiara Zanetti, Alberto Ranghiero, Gabriele Citelli, Chiara Rossi, Marco Lucioni, Umberto Malapelle, Fabio Pagni, Massimo Barberis, Elena Guerini-Rocco, Giuseppe Viale, Nicola Fusco

Summary: Mucoepidermoid carcinoma (MEC) of the breast is a rare tumor characterized by various cell types arranged in solid and cystic patterns. The molecular landscape of breast MECs was investigated, revealing a low histological grade and activation of EGFR/AREG axis. Genetic alterations in PI3K/AKT/mTOR and cell cycle pathways were also observed. These findings suggest that breast MECs may not be as low-risk as previously thought and may potentially benefit from immunotherapy.

CANCER MEDICINE (2023)

Article Oncology

Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas

Marco Lucioni, Sara Fraticelli, Giovanni Santacroce, Arturo Bonometti, Nicola Aronico, Roberta Sciarra, Marco Vincenzo Lenti, Paola Ilaria Bianchi, Giuseppe Neri, Monica Feltri, Benedetto Neri, Giuseppina Ferrario, Roberta Riboni, Gino Roberto Corazza, Alessandro Vanoli, Luca Arcaini, Marco Paulli, Antonio Di Sabatino

Summary: This retrospective study aimed to describe the clinical-pathological characteristics of intestinal T-cell lymphomas (ITCL) and possibly identify their hallmarks. The study included 28 patients, with most cases associated with celiac disease. The presence of CD, peripheral lymphocytosis, advanced Lugano clinical stage, and the histological subtype ITCL-NOS were significantly associated with worse survival.

CANCERS (2023)

Article Hematology

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, Francesco Merli, Stefano Luminari, Caterina Zerbi, Livio Trentin, Alessandro Re, Chiara Rusconi, Simonetta Viviani, Andrea Rossi, Federica Cocito, Barbara Botto, Erika Meli, Antonello Pinto, Irene Dogliotti, Guido Gini, Benedetta Puccini, Francesca Ricci, Luca Nassi, Alberto Fabbri, Anna Marina Liberati, Michele Merli, Andrea Riccardo Filippi, Maurizio Bonfichi, Valentina Zoboli, Germana Tartaglia, Giorgia Annechini, Gianna Maria D'Elia, Ilaria Del Giudice, Isabel Alvarez, Andrea Visentin, Stefano Pravato, Daniela Dalceggio, Chiara Pagani, Silvia Ferrari, Caterina Cristinelli, Tanja Lazic, Virginia Valeria Ferretti, Umberto Ricardi, Luca Arcaini

Summary: In this study, baseline characteristics of 308 consecutive NLPHL patients diagnosed in 19 Italian centers from 2000 to 2018 were retrospectively analyzed. With a median follow-up of 8.4 years for treated patients, the estimated 5-year overall survival was 97.8% and 5-year progression-free survival was 84.5%. After adjusting for various factors, patients with stage II or more showed superior progression-free survival with immunochemotherapy compared to chemotherapy alone.

HEMASPHERE (2023)

Letter Hematology

SARS-CoV-2 Infection in Patients With Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

Irene Defrancesco, Virginia Valeria Ferretti, Pierre Morel, Charalampia Kyriakou, Efstathios Kastritis, Ibrahim Tohidi-Esfahani, Alessandra Tedeschi, Christian Buske, Ramon Garcia-Sanz, Josephine M. I. Vos, Veronica Peri, Gloria Margiotta Casaluci, Angela Ferrari, Francesco Piazza, Rimke Oostvogels, Ester Lovato, Lydia Montes, Luc Matthieu Fornecker, Alexander Grunenberg, Meletios Athanasios S. Dimopoulos, Constantine Tam, Shirley D'Sa, Veronique Leblond, Judith Trotman, Francesco Passamonti, Luca Arcaini, Marzia Varettoni

HEMASPHERE (2023)

Article Hematology

Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel

Pier Luigi Zinzani, Marco Paulli, Luca Arcaini, Emanuel Della Torre, Simone Ferrero, Amalia Figuera, Ferdinando Frigeri, Maurizio Martelli, Elena Sabattini, Riccardo Scarpa, Giovanni Barosi

Summary: This article presents the results of a discussion among Italian experts regarding the clinical needs in managing idiopathic multicentric Castleman disease (iMCD). They issued recommendations for clinical decisions and proposed new research in areas such as diagnostic certainty, siltuximab therapy, and alternatives for patients resistant/intolerant to siltuximab therapy. The article aims to improve the practice of iMCD and inform future studies in the field.

HEMASPHERE (2023)

Editorial Material Hematology

Deciphering molecular complexity of HCV-associated lymphoproliferation

Michele Merli, Francesco Passamonti, Luca Arcaini

Summary: Recent clinical studies have shown that patients with Hepatitis C virus-associated indolent lymphoproliferative disorders (LPD) can achieve lymphoma responses when treated solely with direct-acting antivirals (DAAs). However, the molecular mechanisms underlying LPD responses to DAAs are not well understood. In this paper, the authors provide new molecular insights, reporting intraclonal diversification and persistence of B-cell clones in most cases, even after viral eradication and positive clinical outcomes. These findings suggest that achieving a molecular response may not be necessary for a 'functional cure' in these patients. Further immunogenetic and mutational studies are needed to better understand this biological puzzle and refine treatment strategies.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Correction Oncology

The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (vol 36, pg 1720, 2022)

Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Daniel Boyer, Mariarita Calaminici, Amy Chadburn, John K. C. Chan, Wah Cheuk, Wee-Joo Chng, John K. Choi, Shih-Sung Chuang, Sarah E. Coupland, Magdalena Czader, Sandeep S. Dave, Daphne de Jong, Arianna Di Napoli, Ming-Qing Du, Kojo S. Elenitoba-Johnson, Judith Ferry, Julia Geyer, Dita Gratzinger, Joan Guitart, Sumeet Gujral, Marian Harris, Christine J. Harrison, Sylvia Hartmann, Andreas Hochhaus, Patty M. Jansen, Kennosuke Karube, Werner Kempf, Joseph Khoury, Hiroshi Kimura, Wolfram Klapper, Alexandra E. Kovach, Shaji Kumar, Alexander J. Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson Leung, Vasiliki Leventaki, Xiao-Qiu Li, Megan S. Lim, Wei-Ping Liu, Abner Louissaint, Andrea Marcogliese, L. Jeffrey Medeiros, Michael Michal, Roberto N. Miranda, Christina Mitteldorf, Santiago Montes-Moreno, William Morice, Valentina Nardi, Kikkeri N. Naresh, Yasodha Natkunam, Siok-Bian Ng, Ilske Oschlies, German Ott, Marie Parrens, Melissa Pulitzer, S. Vincent Rajkumar, Andrew C. Rawstron, Karen Rech, Andreas Rosenwald, Jonathan Said, Clementine Sarkozy, Shahin Sayed, Caner Saygin, Anna Schuh, William Sewell, Reiner Siebert, Aliyah R. Sohani, Ritsuro Suzuki, Reuben Tooze, Alexandra Traverse-Glehen, Francisco Vega, Beatrice Vergier, Ashutosh D. Wechalekar, Brent Wood, Luc Xerri, Wenbin Xiao, Norah Olubunmi Akinola, Yassmine Akkari, Luis M. Allende, Katsuyuki Aozasa, Iguaracyra Araujo, Luca Arcaini, Kirit M. Ardeshna, Naoko Asano, Andishe Attarbaschi, Chris M. Bacon, Sharon Louise Barrans, Tracy Batchelor, Maxime Battistella, Linda B. Baughn, Amir Behdad, Sigbjorn Berentsen, Giada Bianchi, Jacob Bledsoe, Peter Borchmann, Mark Bower, Barbara Buldini, Jan Andreas Burger, Birgit Burkhardt, Ryan D. Cassaday, Giovanni Cazzaniga, Nadine Cerf-Bensussan, Ethel Cesarman, Mammen Chandy, Jennifer R. Chapman, Bjorn Chapuy, Xueyan Chen, Chee Leong Cheng, Carlos Chiattone, Nicholas Chiorazzi, Lucy B. Cook, Wendy A. Cooper, Gregory Philip Corboy, Andrew John Cowan, Immacolata Cozzolino, Ian A. Cree, Emanuele S. G. d'Amore, Andrew John Davies, Martina Deckert, Jan Delabie, Elizabeth G. Demicco, Vikram Deshpande, Arjan Diepstra, Daan Dierickx, Kieron Dunleavy, Barbara Eichhorst, Daisuke Ennishi, David C. Fajgenbaum, Pedro Farinha, Carlos Fernandez de Larrea, Kevin E. Fisher, Jude Fitzgibbon, Melina Flanagan, Jonathan Fromm, Juan F. Garcia, William Robert Geddie, Morie Gertz, Ajay Gopal, Satish Gopal, Patricia Theresa Greipp, Alejandro Gru, Ritu Gupta, Martin-Leo Hansmann, Konnie M. Hebeda, Klaus Herfarth, Marco Herling, Olivier Hermine, Khe Hoang-Xuan, Jennelle Hodge, Shimin Hu, Yuhua Huang, Yin Pun Hung, Stephen Hunger, Hiroto Inaba, Hiroshi Inagaki, Javeed Iqbal, Kenji Ishitsuka, Noriko Iwaki, Keiji Iwatsuki, Nitin Jain, Yoon Kyung Jeon, Marshall Kadin, Sachiko Kaji, Aanchal Kakkar, Anastasios Karadimitris, Keisuke Kataoka, Seiichi Kato, Marie Jose Kersten, Rhett P. Ketterling, Ji Eun Kim, Christian P. Kratz, Robert Kridel, Sigurdur Kristinsson, Ralf Kuppers, Isinsu Kuzu, Yok-Lam, Ann Lacasce, Laurence Lamant-Rochaix, Thierry Lamy, Ola Landgren, Siddhartha Laskar, William Bradlyn Laskin, Georg Lenz, Shaoying Li, Gan Di Li, Pei Lin, Franco Locatelli, Robert Brian Lorsbach, Izidore Lossos, Thomas P. Jr Loughran, William R. Macon, Joseph J. Maleszewski, Pankaj Malhotra, Teresa Marafioti, Dai Maruyama, Alexander Marx, Sam M. Mbulaiteye, Veronique Meignin, Ester Mejstrikova, Pamela Michelow, Markku Miettinen, Rodney R. Miles, Hiroaki Miyoshi, Thierry Jo Molina, Manuela Mollejo, Shuji Momose, Tetsuya Mori, William G. Morice, Bertrand Nadel, Hirokazu Nagai, Motoo Nagane, Reena Nair, Naoya Nakamura, Atsuko Nakazawa, Samih Nasr, Andrew Gordon Nicholson, Alina Nicolae, Robert Shigeo Ohgami, Naoki Oishi, Timothy S. Olson, Nicolas Ortonne, Bruno Paiva, Qiang Pan-Hammarstrom, Mayur Parihar, Marco Paulli, Andrea Petersen, Jennifer Picarsic, Alessandro Pileri, Nicola Pimpinelli, Jose A. Plaza, Karen R. Rabin, Markus Raderer, Kanti Rai, Ulla Randen, Huilan Rao, Alistair Robson, Rosemary Rochford, Richard Rosenquist, Davide Rossi, Esther D. Rossi, Simon Rule, Grzegorz Rymkiewicz, Elena Sabattini, Vaskar Saha, Mamiko Sakata-Yanagimoto, Christian A. Sander, J. Martin Sangueza, Omar P. Sangueza, Marco Santucci, Yasuharu Sato, Akira Satou, Kristian Theo Schafernak, Fernando Schmitt, Gianpietro Semenzato, Manju Sengar, Tait Shanafelt, Kazuyuki Shimada, Graham W. Slack, Susan Slager, Riccardo Soffietti, David A. Solomon, Kostas Stamatopoulos, Christian Steidl, Stephan Stilgenbauer, Narittee Sukswai, Kengo Takeuchi, Giovanni Tallini, Junichi Tamaru, Soo-Yong Tan, Prashant Tembhare, Enrico Tiacci, Yoshiki Tokura, Olivier Tournilhac, Steven Treon, Lorenz Truemper, Kunihiro Tsukasaki, Frits van Rhee, Abraham Varghese, Maarten H. Vermeer, Philippe Vielh, Brian Walker, Michael Wang, Huan-You Wang, Zhe Wang, Takashi Watanabe, Oliver Weigert, David Wein-Stock, Sean J. Whittaker, Rein Willemze, Wilhelm Woessmann, Catherine J. Wu, Motoko Yamaguchi, Hidetaka Yamamoto, Daisuke Yamashita, Shenmiao Yang, David T. Yang, Takahiko Yasuda, Wei-Hua Yin, Yoh Zen, Sha Zhao, Wei-Li Zhao

LEUKEMIA (2023)

Article Oncology

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie-Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig

Summary: The immune checkpoint inhibitor durvalumab shows potential as a strategy for enhancing immune responses and improving standard therapies in patients with hematologic malignancies. This study evaluated the safety and efficacy of durvalumab in combination with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL) and found limited benefits of durvalumab monotherapy or combination therapy.

CANCER REPORTS (2023)

No Data Available